Core Viewpoint - The article discusses the IPO of Shanghai Linqingxuan Biotechnology Co., Ltd., highlighting its high-end positioning in the skincare market and the success of its flagship product, Camellia Oil, which has achieved significant sales and profitability growth since its launch [1][2][3]. Group 1: Company Overview - Linqingxuan was founded in 2003, launching its flagship brand in 2004 and opening its first store in 2008. The company officially introduced its core product, Camellia Oil, in 2014, targeting the facial oil segment [4]. - The market for facial oils in China has grown from 900 million yuan in 2019 to an expected 5.3 billion yuan by 2024, with a compound annual growth rate (CAGR) of 42.8% [4]. Group 2: Financial Performance - Revenue increased from 691 million yuan in 2022 to 805 million yuan in 2023, and is projected to reach 1.21 billion yuan in 2024, with a CAGR of 32.3% [7]. - The company turned a profit from a loss of 5.93 million yuan in 2022 to a net profit of 85 million yuan in 2023, and further to 187 million yuan in 2024 [8]. - Gross margins have improved from 78.0% in 2022 to 82.5% in 2024 [9]. Group 3: Product Strategy - The company focuses on a single flagship product, Camellia Oil, which has maintained the top position in the facial oil market for 11 consecutive years and is the only product in this category to exceed 100 million yuan in retail sales for eight years [6]. - The product pricing strategy ranges from 200 yuan to 800 yuan, with premium products priced as high as 1,880 yuan for a 50ml cream [5]. Group 4: Marketing and Sales Channels - Linqingxuan has invested 760 million yuan in marketing over three years, although it faced penalties for false advertising [11][13]. - The company has expanded its retail presence to 506 stores by the end of 2024, with over 95% located in shopping malls [18]. - Online sales have surged, with revenue from online channels increasing from 312 million yuan in 2022 to 714 million yuan in 2024, surpassing offline sales for the first time [20]. Group 5: Investment and Valuation - The company has attracted significant investment from notable firms, completing multiple funding rounds and achieving a pre-IPO valuation of approximately 3.84 billion yuan [26]. - Comparatively, Linqingxuan's revenue of 1.21 billion yuan in 2024 is smaller than that of other listed beauty companies, raising questions about its ability to meet IPO valuation expectations [27].

Core Viewpoint - The acquisition of the functional skincare brand Baizhicui by the makeup brand Judo's parent company, Juyi Group, marks its official entry into the skincare sector, reflecting a broader trend of multi-brand and cross-category development in the beauty industry [1][2]. Category Expansion: Skincare/Makeup/Medical Devices - Skincare brands are primarily venturing into makeup and fragrance, while makeup brands are increasingly extending their reach into skincare [3][4]. - The mainstream choice for skincare brands entering the makeup market is to launch base makeup products, followed by fragrances [5]. Skincare Brands Entering Makeup Market - Notable brands like Proya, Han Shu, and Baique Ling have launched cushion products, while others like Natural Hall and Oushiman have introduced foundation products [5][6]. Skincare Brands Focusing on Medical Devices - Skincare brands are showing a strong interest in the medical device category, primarily launching products featuring recombinant collagen [6][7]. Makeup Brands Entering Skincare Market - Makeup brands are primarily focusing on masks as their first choice for skincare products, followed by serums and creams [8][9]. - The low technical requirements and acceptance of masks make them an attractive entry point for makeup brands [10]. Product Pricing Strategies - Skincare brands typically price their makeup products below 200 yuan, with many under 100 yuan, while makeup brands entering skincare tend to target mid to high-end price ranges [13][14]. - Medical device products from skincare brands have a wider pricing range, with some products priced as high as 300 yuan [13]. Market Performance - Sales figures for newly launched products vary significantly, with some brands achieving over 10,000 units sold, while others struggle to reach even 100 [15][16]. - For instance, the luxury caviar mask from Mao Ge Ping has sold over 100,000 units, contributing significantly to the brand's revenue [17]. Challenges in Cross-Category Development - The drive for cross-category development is largely due to rising traffic and customer acquisition costs, as well as the saturation of single-category growth [18]. - Successful cross-category ventures depend on the ability to transfer existing consumer perceptions to new product categories [19].

Core Viewpoint - The company, Xi'an Juzhi Biological Gene Technology Co., Ltd. (referred to as "Juzhi Biological"), has issued a statement addressing controversies surrounding its recombinant collagen product, Kefu Mei, emphasizing its commitment to quality standards and ongoing improvements in response to industry developments [1][2]. Group 1: Company Background and Standards - Juzhi Biological applied for the first domestic invention patent related to recombinant collagen in 2001, naming the innovative substance "human-like collagen" and applying for the "human-like" trademark [1]. - The company has accumulated over 20 years of technical expertise, transitioning the substance from laboratory research to industrial application [1]. - Multiple industry standards related to recombinant collagen have been established, including the 2021 "Guidelines for Naming Recombinant Collagen Biological Materials" and the 2022 medical industry standard YY/T 1849-2022 [1]. Group 2: Quality Control and Self-Inspection - The company claims that its product development and production adhere to established standards, implementing quality control measures for raw materials and products [2]. - In response to the controversies, Juzhi Biological conducted a comprehensive self-inspection of all production, testing, and labeling processes, validating different testing methods [2]. - The company acknowledged limitations in its existing quality standards and testing methods, indicating a need for continuous optimization to meet evolving industry standards [2]. Group 3: Controversy and Response - The controversy began when a beauty blogger accused Juzhi Biological's Kefu Mei product of ingredient fraud, claiming the actual collagen content was only 0.0177% [3]. - Juzhi Biological refuted these claims, stating that their testing results showed collagen content exceeding 0.1%, contradicting the blogger's assertions [3]. - The dispute centers on differing testing methods, with both parties accusing each other of using "unscientific" approaches, as there are currently no national standards for testing recombinant collagen in cosmetics [3]. Group 4: Market Impact - As of June 23, Juzhi Biological's total market value was HKD 54.83 billion, reflecting a nearly 40% decline from its peak on May 20 [4].

Core Viewpoint - The company has issued a statement regarding the standards and developments related to recombinant collagen products, highlighting the need for continuous improvement in quality standards and testing methods to meet industry demands and consumer expectations [1][2]. Group 1: Industry Standards - In 2021, the guideline for naming recombinant collagen biomaterials was published and implemented [1] - In 2022, the pharmaceutical industry standard YY/T 1849-2022 for recombinant collagen was published and implemented [1] - In 2023, the pharmaceutical industry standard YY/T 1888-2023 for recombinant humanized collagen was published and implemented [1] - In 2023, the group standard T/ZGKSL 004-2023 for recombinant collagen raw materials used in cosmetics was published and implemented [1] - In 2025, the pharmaceutical industry standard YY/T 1947-2025 for recombinant collagen dressings is set to be published, with implementation in March 2026 [1] Group 2: Company Response and Actions - The company has conducted a comprehensive self-inspection of all aspects of production, testing, and labeling in response to recent discussions about the recombinant collagen content in its products [1] - The company acknowledges the limitations of its current quality standards, testing methods, and labeling, which need to be optimized to align with industry advancements and high consumer expectations [2] - The company plans to collaborate with research institutions to accelerate the optimization and validation of qualitative and quantitative testing methods for recombinant collagen in cosmetics [2] - The company aims to gradually disclose key technical parameters and quality control data for raw materials and finished products to empower industry development and accept public supervision [2] - The company will continue to participate in the formulation of national and industry standards related to recombinant collagen in cosmetics to promote standardized industry development [2]

证券代码：603605 证券简称：珀莱雅 公告编号：2025-030 债券代码：113634 债券简称：珀莱转债 珀莱雅化妆品股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 珀莱雅化妆品股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 19 日分别召开了第四届董事会第三次会议、2024 年年度股东大会，审议 通过了《关于变更公司注册资本并修订 <公司章程> 及办理工商变更登记的议案》。 具体内容详见公司于 2025 年 4 月 25 日在上海证券交易所网站 （www.sse.com.cn） 披露的《珀莱雅化妆品股份有限公司关于变更公司注册资本并修订 <公司章程> 及办理工商变更登记的公告》（公告编号：2025-012）。 董 事 会 名称：珀莱雅化妆品股份有限公司 统一社会信用代码：91330100789665033F 类型：其他股份有限公司（上市） 法定代表人：侯军呈 注册资本：叁亿玖仟陆佰贰拾肆万柒仟陆佰零陆元 成立日期：2006 年 05 ...

证券研究报告 | 北交所定期报告 | | --- | hyzqdatemark 2025 年 06 月 23 日 证券分析师 赵昊 SAC：S1350524110004 zhaohao@huayuanstock.com 王宇璇 SAC：S1350525050003 wangyuxuan@huayuanstock.com 下游日化行业发展促进香精香料行业稳步增长，关注北交所相关标的 ——北交所消费服务产业跟踪第十九期（20250620） 投资要点： 请务必仔细阅读正文之后的评级说明和重要声明 联系人 香精香料市场前景向好，下游化妆品行业繁荣拉动需求。2023 年中国香料香精行业 市场规模约为 439 亿元，同比增长 2.6%，预计 2026 年有望突破 500 亿元。随着中 国居民生活水平的提高与消费结构的升级，日化、食品等行业在下游需求的推动下 得到了持续发展，也为香料香精产业链的上游和中游企业提供了广阔的市场空间和 机遇。2023 年中国化妆品市场规模约为 5169.0 亿元，同比增长 6.4%，2025 年有 望增至 5791.0 亿元。化妆品生产通常可分为自主生产和代工生产两种模式，人群、 渠道、品牌多 ...

夏至刚至，没想到比天气先"热"起来的是花西子。 2 0 2 5年6月2 2日，上海港汇恒隆广场负一层迎来一个新面孔——花西子上海首店正式开业，即 使细雨濛濛也没能挡住大量消费者进店体验。 在轩窗勾勒的"琉璃花影壁"前，顾客李女士脱口而出：" 终于在线下看到了花西子！ "而这句 朴素心声的背后，隐藏着大量值得挖掘的信息。 《FBe a u t y未来迹》经过实地采访和调研后发现，这个店虽然只有大约6 0平方米的面积，但对 花西子品牌的未来布局来说具有战略支点意义。 首先，从入驻商场来看，花西子选择的都是能进一步拉高品牌势能的价值高地。 公开资料显示，上海港汇恒隆广场于1 9 9 9年1 2月开业，其不仅是香港恒隆集团在中国大陆地 区首个集商场、办公楼及服务式公寓于一身的商业综合体，更被誉为中国高端购物中心的"开 山之作"。 自2 0 1 7年启动升级后，LV、Gu c c i、卡地亚等高端品牌以双层旗舰店形态入驻，使其成为众 多高端品牌在上海的战略要地。花西子所在的B1层被定位为"高端美妆香氛专区"，成为香奈 儿、迪奥、希思黎、祖·玛珑等国际一线品牌独立门店或精品柜的聚集地。此外，恒隆广场还 以"首店经济"为引 ...

Core Insights - The National Medical Products Administration (NMPA) reported that the compliance rate for sunscreen products in the 2024 sampling inspection was 95.01%, the lowest among 12 categories of cosmetics [1][8] - Out of 640 batches of non-compliant cosmetics, 149 batches were sunscreen products, accounting for over 23% of the total non-compliance [1][6] Group 1: Compliance and Inspection Data - In the past year, from May 1, 2024, to April 30, 2025, the NMPA disclosed 640 batches of non-compliant cosmetics, with 149 batches being sunscreen products, representing 23.28% of the total [1][6] - The overall compliance rate for all inspected cosmetics was 97.79%, with 20,889 batches meeting the standards out of 21,362 batches inspected [6][8] Group 2: Issues with Sunscreen Products - The majority of issues with sunscreen products were related to ingredient compliance, with many products failing to meet the specified ingredient requirements or having extremely low concentrations of active ingredients [2][19] - A total of 253 non-compliance items were identified in the 149 batches of sunscreen products, with 121 instances related to ingredient comparison, accounting for 47.83% of the issues [19][20] Group 3: Regulatory Changes and Focus Areas - The NMPA's new "Cosmetic Safety Risk Monitoring and Evaluation Management Measures" will take effect on August 1, 2024, aimed at enhancing supervision and risk assessment in the cosmetics sector [2][23] - The new regulations will focus on monitoring and evaluating risk factors that may affect cosmetic quality and safety, particularly substances that could harm human health [23][24] Group 4: Regional Insights and Industry Trends - Guangdong Province accounted for 84.56% of the non-compliant sunscreen products, with 126 out of 149 batches having production licenses from this region [9][12] - The cosmetics industry in Guangdong is significant, with over 3,342 production enterprises and a production value exceeding 200 billion yuan, representing the largest share in the country [12][18]

Core Insights - The Chinese cosmetics market is projected to reach a retail total of 1,073.8 billion yuan in 2024, with domestic brands increasing their market share from 52% to 55%, marking a historic turning point where Chinese brands gain dominance in the "trillion club" [1] - The rise of domestic brands is attributed to a systematic evolution of the commercial ecosystem, driven by government policies, scientific research, consumer behavior, talent development, and cultural integration [2] Policy Support - The regulatory framework established by the national drug monitoring system has created a balance between safety and innovation, enhancing industry professionalism and competitive barriers [4] - The implementation of the new Cosmetics Supervision and Administration Regulations since 2021 has ushered in a strong regulatory era, promoting compliance and accelerating industry evolution [4] Research and Development - Companies in the Chinese cosmetics industry are increasing R&D investments, with a significant number of global patent applications related to cosmetics originating from China [5] - Domestic brands are narrowing the technological gap with foreign brands by integrating resources and focusing on independent innovation [5] Consumer Behavior - The Chinese market remains the largest cosmetics consumer globally, with changing consumer preferences emphasizing quality and value [6] - The Z generation shows a strong preference for domestic brands, while older consumers are also contributing to the growth of the anti-aging market [6] Talent Development - Over 20 universities in China have established programs related to cosmetics technology, fostering a new generation of professionals in the industry [7] - Leading companies are focusing on organizational agility and efficiency to maintain competitive advantages in a challenging market [7] Cultural Integration - The rise of the "new national trend" movement has led domestic beauty brands to incorporate Chinese cultural elements into their narratives, enhancing their appeal [8] - A significant percentage of young consumers express a higher willingness to purchase products that feature national trend elements [8] Industry Evolution - The convergence of policy, market dynamics, technology, talent, and culture provides unprecedented support for domestic cosmetics brands [9] - Despite the growth, challenges such as global supply chain restructuring and intense domestic competition remain, necessitating a focus on quality and cultural identity [10] Brand Development Conference - The China Cosmetics Association is organizing a brand development conference aimed at installing three key engines for industry evolution [11] - The conference will release authoritative rankings and discuss sustainable growth strategies, addressing industry pain points and fostering collaboration [12][14] Historical Context - The evolution of the Chinese cosmetics industry can be categorized into three phases: from imitation to independent innovation, and now to global expansion [25] - The current phase emphasizes the importance of brand value and cultural identity as key competitive advantages [27]

Investment Rating - The report maintains an "Overweight" rating for the retail industry [1] Core Insights - The 2025 618 shopping festival has been extended compared to 2024, with simplified discount rules, leading to strong performance from domestic beauty brands [3][8] - Tmall's overall GMV (Gross Merchandise Volume) during the 618 festival is expected to grow by 10% year-on-year, marking the highest quality growth in three years, with total e-commerce sales reaching 855.6 billion yuan, a 15.2% increase [3][9] - The beauty sector on Tmall is projected to see a year-on-year growth of 11.1%, accounting for 41.3% of the overall market [3][9] - Key domestic brands like Proya and Han Shu have secured top positions on Tmall and Douyin, while international brands are also regaining market share [3][9][11] - The pet food segment continues to show high growth, with significant increases in sales for various pet food categories [3][12] Summary by Sections Industry Trends - The 2025 618 shopping festival features a more refined promotional timeline, with a focus on simplified discount rules and stable promotional intensity [3][8] Sales Performance - Tmall's beauty sales during the 618 festival are expected to grow by 11.1%, with Proya and Han Shu leading the rankings on Tmall and Douyin respectively [3][9][11] - The overall e-commerce sales during the 618 festival reached 855.6 billion yuan, reflecting a 15.2% year-on-year growth [3][9] Investment Recommendations - The report suggests focusing on companies with upward momentum and new product catalysts, such as Ruoyu Chen, Shangmei Co., Guibao Pet, and Zhongchong Co., as well as those with attractive valuations like Maogeping, Proya, and Juzibio [3][12] Market Review - The report notes a decline in the retail index by 2.75% for the week of June 16-20, 2025, with a year-to-date decline of 7.89% [13][17] Company Valuation Table - The report includes a valuation table for various companies, indicating their market capitalization, closing prices, and projected earnings [19]